Physiology of Body Weight, Weight Gain and Adipose Tissue Background 



Importance of Topic to Practice
For years, individuals with larger bodies have been told by medical providers, government agencies and society in general that having a higher body weight is harmful to one’s health and the health care system (1-3). Individuals with a higher body weight are often subjected to weight bias, stigma and discrimination (1) and are often told to lose weight in efforts to improve their health. Until recently, much of the global health care education and public health messaging has been rooted in individual responsibility for weight control, emphasized by an “eat less/move more” mentality with the goal of achieving a ‘healthy’ weight. This has been extrapolated from previous human physiology evidence that states energy balance is achieved by having equal energy intake to energy expenditure based on the principal law of thermodynamics (4,5). Weight gain is therefore a result of excessive energy intake or inadequate energy expenditure, while weight loss is achieved by reducing energy intake and/or increasing energy expenditure (6,7). These basic thermodynamic principles have caused a culture of dieting, caloric restriction and weight-loss-centric thinking, which has contributed to the growing evidence on weight stigma (See Additional Content: Weight Stigma Background). Advances in the science of, and the social impact of, weight stigma as well as advances in biology, physiology and metabolic studies have changed the understanding of the factors that affect weight regulation and eating behaviours. These include the metabolic function of adipose tissue, genetic factors affecting weight, metabolic adaptation in response to weight change and differences between non- and pathophysiological body weights. Outdated evidence and a lack of understanding about the complex intersections affecting body weights may result in health care professionals and the public at large feeling confused. This background paper provides an updated understanding of the physiological factors contributing to body weight regulation and appetite changes in response to weight change, based on the best available evidence at the time of writing. Applying this updated evidence to clinical practice may support a better client-provider relationship and potentially decrease weight-related bias and stigma in the nutrition field.  
Topic Overview
Most public health and clinical health messaging has used epidemiological studies that define healthy weights using BMI. Studies have continually found a U-shape association with lower and higher BMI categories with morbidity (health) and mortality (death) risks (8,9). Over the past three decades, rates of higher weights have increased and continue to be reported as a health and economic crisis (3,8,10,11). Historically, having a BMI >30 kg/m2 was defined as ‘obesity’ and was associated with an increased risk of diabetes, cardiovascular disease and some cancers (12-17), resulting in decades of research, public health campaigns and societal messaging targeting weight loss efforts to achieve ‘healthy weights’ (BMI 18.5-24.9 kg/m2) (18,19). Despite the efforts to reduce the incidence of obesity (using BMI definitions) or treating obesity via weight loss, weight gain has continued to rise (20) and has further perpetuated weight bias, stigma and discrimination among individuals with higher body weight. See Additional Content: Weight Stigma Background.
Recent progress in animal and human studies exploring the genetic, physiological and metabolic variances across weight spectrums has changed the understanding of body weight and health, suggesting that having a higher body weight may not be associated with poor health at the individual level (21-23). In 2020, the Canadian Adult Obesity Clinical Practice Guidelines recommended against using BMI to define obesity at the individual level (24,25) and instead recommended an updated definition (“defined as abnormal or excess adipose tissue impairing health”) reflecting the evidence in genetics, metabolic/physiological, environmental and social determinants of health impacting body weight (specifically adipose tissue) (24). The shift in definition has been echoed in literature (26-29) and accepted by a number of organizations (30-37) and countries (38-43) but remains a topic of controversy (44-47). Redefining obesity beyond BMI classifications serves to support cellular and organ-level evidence that adipose tissue dysfunction can occur across all weight spectrums, similar to other organ-specific diseases that occur across weight spectrums such as diabetes, chronic kidney disease or atherosclerosis (48). This narrative supports body diversity by acknowledging that body weight and BMI are not indicators of health or disease processes (27,49,50) and that focusing on health-related behaviour changes is universal regardless of one’s body weight, size or BMI (51,52). 

Relevant Basic Information
Review of Adipose Tissue
Evidence at the genetic and cellular level of adipose tissue has contributed to further understanding that adipose tissue (adipocytes) is essential for metabolic and endocrine-related mechanisms in the body rather than purely an innate organ that stores excess energy (53). Furthermore, these endocrine functions stimulate hormones, enzymes and other endocrine-communication modulators that affect human survival and metabolism (54).
Adipose tissue, specifically adipocytes, are heterogenous in nature both metabolically and genetically (54,55). Adipocytes can increase in size, known as adipocyte hypertrophy, and can increase in the number of adipose cells, known as adipocyte hyperplasia (54). The human body has various adipose deposit sites, primarily known as subcutaneous adipose tissue (typically distributed in extremities – hips, legs, arms), and visceral adipose tissue (centrally distributed around organs) (54). The location and action of adipose tissue is the most important, as increased adipose tissue (by hypertrophy or hyperplasia) does not necessarily indicate a disease process; however, like any tissue, it can become dysfunctional by secreting a variety of biologically active molecules called adipokines, that can modulate inflammation (54,55). When adipocytes progress to release these inflammatory molecules (adipokines), this can lead to ectopic fat deposits in pancreatic ß-cells, skeletal muscle and the liver, leading to changes in metabolic regulation such as severe insulin resistance, hypertriglyceridemia, hepatic steatosis and metabolic syndrome (55,56). 
Animal and human studies have revealed that adipose tissue is highly metabolic, having a role in energy balance via secreting hormones that control body weight, food intake and insulin balance (54). One particular discovery is the hormone leptin, primarily produced by adipocytes, that decreases feeding and increases energy expenditure by acting on the leptin receptors (LEPR) in the hypothalamus of the brain (57,58). Leptin’s main role is to regulate long-term energy intakes; however, in periods of starvation or insufficient caloric intake (as seen in "dieting" practices), the loss of adipose tissue results in equal losses of leptin (59-61). This loss of leptin stimulates the brain to release hormones to increase food intake and conserve energy by decreasing energy expenditure, which for some individuals can lead to leptin resistance (59-61). As a result of the discovery of leptin, adipose tissue is no longer viewed only as a storage organ, rather it is crucial in controlling energy balance, appetite, immune function and adapting to changes (weight gain or loss), which is essential for survival (62). Moreover, research on leptin and the endocrine functions of adipose tissue has uncovered further evidence in genetic variations and differences in weight regulation.    
Genetic Evidence Affecting Weight
Scientific advances in biological studies have shed light on genetic factors that influence the understanding of body weight/body fat variations. Some individuals are genetically susceptible to increasing weight (adipose tissue) (63,64), which can be largely influenced by family history and ethnicity (65). Large genetic studies by Locke (n=339,224) and Shungin (n=224,459) have found specific genes and alleles responsible for increased weight and body fat traits, primarily found in regions of the brain (melanocortin-4-receptor (MC4R) pathway) associated with controlling hunger (63,66). Specific gene mutations, such as the LEPR, proopiomelanocortin (POMC) and Bardet-Biedl Syndrome (BBS) among many others, have been found to influence appetite control, food intake and energy balance (64,67,68) (See Table 1). This is consistent in both human and animal studies (64,68-70). Various genetic markers conducted in twin, family and adoption studies have concluded that 40-70% of body weight or adipose tissue is genetically based (71) with over 50 genes that are associated with elevated adipose tissue (72). Despite a small proportion (~10%) of single-gene variations (See Table 1) found to date that are responsible for body weight status, multiple gene variations (known as polygenics) are common and in individuals who carry such gene variants, their risk of gaining adipose tissue is 20-30% higher than individuals who do not carry such genes (65).
Regardless of one’s predisposition to higher weights or higher percent body fat, a meta-analysis (n≥218,166) concluded that carrying weight-promoting gene variants (i.e. FTO gene) increases the risk of having higher weight by 23% compared to adults who do not carry such genes (73). Thus, individuals who are susceptible to higher body weights may need to have more support to adopt health-related behaviours if their weight is impairing their health (medical, functional and mental health), similar to those with genetic forms of diabetes, heart disease or dyslipidemia. This should not be interpreted as weight loss or healthy eating and physical activity behaviours be promoted solely to individuals with higher body weights, rather that all body sizes and health conditions (regardless of weight) should implement health behaviour changes. Furthermore, health care providers should be aware that genetic influences could account for a portion of their patient/client roster, providing an opportunity to counteract self-blame and accept body diversity.  

Table 1: Rare Genetic Forms of Higher Weight Variations Associated with Increased Appetite 
Proopiomelanocortin (POMC) Deficiency (74,75)
  • Severe weight gain beginning early in life (>95 percentile for BMI growth chart) 
  • Excessive eating due to hyperphagia
  • Endocrine abnormalities (adrenocorticotropic hormone deficiency, mild hypothyroidism)
  • Red hair/light skin pigmentation
Leptin Receptor (LEPR) Deficiency (76)
  • Severe weight gain beginning early in life
  • Excessive eating due to hyperphagia
  • Hyperinsulinemia
  • Endocrine abnormalities (hypogonadotropic hypogonadism, hypothyroidism)
  • Early adulthood type 2 diabetes 
Bardet-Biedl Syndrome (BBS) (77,78)
  • Severe weight gain beginning early in life (early onset by age 5 years) 
  • Insatiable hunger (hyperphagia)
  • Cognitive impairment
  • Polydactyly (born with an extra finger or toe)
  • Renal dysfunction 
  • Visual impairment
Alström Syndrome (79) 
  • Severe weight gain beginning early in life (early onset before age 1 year)
  • Short stature in adulthood
  • Progressive visual/auditory impairment
  • Insulin resistance/type 2 diabetes
  • Hyperlipidemia
  • Progressive kidney dysfunction
Review of Energy Expenditure 
Evidence in human physiology states that energy balance is achieved by having equal energy intake to energy expenditure based on the principal law of thermodynamics (4,5). Weight gain is therefore the result of excessive energy intake or inadequate energy expenditure, while weight loss is achieved by reducing energy intake and/or increasing energy expenditure (6,7). Although these principles apply in theoretical contexts, there are considerable interindividual variances in response to changes in energy expenditure (80). 
Total energy expenditure (TEE) consists of three components (Table 2):
  1. Resting energy expenditure (REE), also referred to as resting metabolic rate (RMR) or basal metabolic rate (BMR)
  2. Thermic effect of food (TEF), also known as diet-induced thermogenesis (DIT)
  3. Physical activity energy expenditure (PAEE), also known as activity-related energy expenditure (AEE). PAEE is divided further into involuntary energy expenditure called non-exercise activity thermogenesis (NEAT), which includes movements like fidgeting or unplanned activities, and voluntary energy expenditure called exercise activity thermogenesis (EAT), which includes planned activities. Recent discoveries have further understood these components to have a greater impact on weight regulation, which include alterations in energy expenditure in response to weight loss (80,81). This is known as adaptive thermogenesis (AT). 

Table 2: Components of Total Energy Expenditure
Percentage (%) of Total Energy Expenditure (TEE)
Components of Energy Expenditure (EE)
Other Terms/Names
Resting Energy Expenditure (REE)
Resting Metabolic Rate (RMR)
Basal Metabolic Rate (BMR)
Thermic Effect of Food (TEF)
Diet-induced Thermogenesis (DIT)
Physical Activity Energy Expenditure (PAEE)
  • Non-Exercise Activity Thermogenesis (NEAT)
  • Exercise Activity Thermogenesis (EAT)
Activity-related Energy Expenditure (AEE)
Adaptive Thermogenesis (Metabolic Adaptation) 
Body weight (specifically, adipose tissue) is tightly controlled by the MC4R pathway in the brain, which is thought to maintain a level of adipose tissue for evolutionary survival (82-84) and control energy balance (85,86). The MC4R pathway supports eating behaviours by telling other parts of the brain and body when to stop eating, promotes feelings of satiety and assists in controlling adipose tissue (body weight) (87) (See Figure 1). In some individuals with elevated adipose tissue, there are interruptions in the MC4R pathway, which may contribute to elevated appetite, constant hunger and lower ability to burn calories (88,89). In times of energy depletion (as seen in reduced caloric diets), adipose tissue loss is seen as a negative result and compromises survival, initiating a cascade of neurological, endocrinological and metabolic responses that drives the body to restore body fat to its original state (typically, an individual’s highest body weight) by increasing hunger and decreasing fullness (82,90-92). Physiological research has coined this the body’s “set point” (93), in attempts to restore lost weight (body fat).
Changes in body weight do not follow a linear line and therefore predictive energy expenditure calculations are not accurate in humans (80,81,94,95). A rigorous systematic review and meta-analysis by Dhurandhar, et al. investigated the compensatory change of energy intake and expenditure and found that decreasing caloric intake to induce a prescribed weight loss will result in less weight loss than estimated given the adaptive thermogenesis (metabolic adaptation) that occurs (81). In fact, when no behavioural interventions are considered, dietary interventions alone account for 12-44% less weight loss than expected and exercise interventions account for 55-64% (81). Furthermore, Schwartz and Doucet (96) reported resting energy expenditure (REE) decreased by ~15 kcal/kg of weight lost, while Polidori and colleagues estimated that appetite (or desire to eat) increased by ~100 kcal/day for every kilogram of weight lost, which challenges sustainable long-term weight loss (97). Both these studies used group mean values (96,97), suggesting considerable interindividual variances.
   Figure 1 

Description automatically generated
Source: Smith A. Neurohormonal effects on obesity. Bariatric Times. 2017;14(11):10-14. (Used with Permission)

Appetite Changes in Response to Weight Change
Evidence supports genetic, biological and physiological aspects of appetite and eating behaviours, energy balance and adipose tissue that impact weight gain (69,90,91,98,99). It has been a popular belief that decreasing energy intake or increasing energy expenditure would result in a negative energy balance resulting in weight loss (7). However, extensive evidence in animal (100,101) and human studies (96,101-103) has shed light that changes in energy balance (positive and/or negative) are affected by afferent neural and hormonal signals from muscles, viscera and adipose tissue directly affecting the hypothalamus (energy control centre) of the brain (98,101).
In diet and exercise-induced weight loss studies, anorexigenic hormones (GLP-1, CCK, PYY, etc.) are lower after weight loss (91,102), resulting in individuals feeling less satiated despite adequate nutrient and caloric intake. Simultaneously, the orexigenic hormone ghrelin, which stimulates appetite, is higher after weight loss (90,101,102) and found to be sustained, even when body weight/adipose tissue is regained to its original state. Table 3 reviews the neurohormonal mechanisms and actions after weight loss interventions.

Table 3: Neurohormonal Changes Following Weight Loss Interventions 
After Weight Loss* 
After Bariatric Surgery** 
Secreted from gastric mucosa (stomach) 
Increases hunger
Produced by adipocytes in response to increased fat reserves
Regulates body fat stores; regulates long-term energy intake; increases POMC/CART signaling in brain (decreases appetite); decreases NPY/AgRP signals (increases appetite)
L-cells of the ileum (small intestine)
Increases satiety (fullness); reduces gastric emptying
L-cells of the ileum (small intestine)
Increases satiety (fullness); regulates energy intake; reduces gastric emptying
L-cells of the duodenum and jejunum (small intestine)
Increases satiety (fullness); reduces gastric emptying
POMC: Pro-opiomelanocortin; CART: cocaine- and amphetamine-regulated transcript; NPY: Neuropeptide Y; AgRP: gouti-related peptide; PYY: Peptide YY; GLP-1: glucagon-like peptide 1; CCK: cholecystokinin
* Weight loss via dietary and/or exercise interventions
**Bariatric surgical procedures such as Roux-en-Y gastric bypass and sleeve gastrectomy
 ↓: decreased; ↑: increased
The physiological effects of bariatric surgery (formerly known as ‘weight loss surgery’), suggest that weight loss is not the primary reason for appetite changes or metabolic improvements as once believed (106,107). Rather, alterations in gastrointestinal anatomy (specific Roux-en-y gastric bypass and sleeve gastrectomy procedures) blunt or reduce orexigenic hormones that would normally increase hunger (ghrelin), irrespective of any significant weight loss (106,108). Anorexigenic hormones (PYY, GLP-1, CCK) that would typically decrease after diet-induced weight loss (making individuals less full) are found to have the opposite effect after bariatric surgery (Table 3) (107,109-111). Refer to references 109 and 112 for a thorough review of gut hormones and their responses from bariatric surgery. These peripheral changes in appetite-modulating hormones affect the hypothalamus of the brain, whereby metabolic adaptation does not appear to affect the body's defense mechanisms to restore adipose tissue loss as strongly compared to diet-induced weight loss (107,110,111); however, long-term studies are mixed and interindividual variances should be considered. 
Of note, advances in understanding the physiological mechanisms and neurobiological alterations from these surgical interventions have recommended moving beyond weight loss as an outcome (24). Many organizations have renounced the term 'weight loss surgery' as it misrepresents the actions and mechanisms, replacing it with ‘metabolic or bariatric surgery’, highlighting the above-mentioned findings. This is not universally adopted and therefore is a source of confusion in the public and professional realms (24). Moreover, advances in metabolic and bariatric surgery are expanding the knowledge and opportunities for pharmacological options (113) that target the neurohormonal responses to metabolic adaptation as well as advances in the MC4R pathways of the brain (114). Similar to advances in metabolic conditions (e.g. diabetes, cardiovascular disease and some cancers), pharmacotherapy interventions are targeting biological and physiological mechanisms that treat the root issues affecting inflammation at the cellular level. Further quality research and efficacy is underway and future evidence may identify which interventions may work for long-term use.
Weight changes are highly variable, genetically determined and tightly controlled by complex mechanisms in the brain and organs, including adipose tissue. Understanding the physiological drivers that defend against weight loss (specifically adipose tissue and energy regulation) allows clinicians to appreciate that body weight is highly controlled by pathways in the brain and peripheral hormones in the body affecting weight regulation and eating behaviours. 

Patients/clients seeking weight-related support from dietitians should be made aware of the complexity of weight and appetite regulation. Providers should review the risks and benefits of weight loss from interventions that result in caloric deficiency as well as address neurobiological changes that may occur. Despite the physiological effects of weight changes from diet-induced weight loss, many clients/patients have previously sought out weight loss interventions in the past and may already be at risk for long-term weight gain or appetite changes in response to losing weight (already affected by metabolic adaptation). 
Dietitians can offer a variety of nutrition interventions that are evidence-based and focus on improving health-related outcomes and quality of life goals (i.e. managing hunger, satiety, cravings, etc.), rather than achieving weight loss ideals (34,115). In 2020, the Medical Nutrition Therapy chapter of the Canadian Adult Obesity Clinical Practice Guidelines reviewed evidence that supports a variety of approaches, emphasizing an individualized client-centred nutrition approach (115). These evidence-based guidelines include the use of non-dieting or weight-inclusive approaches that foster health, emotional well-being and quality of life improvements.

See Additional Content:
Advances in genetic, physiological and metabolic research are starting to contribute to the awareness of how harmful messages targeting weight loss or ‘healthy weights’ have had on individuals with larger bodies. However, these advances also provide insight and support for patients/clients that have experienced a lifetime of weight cycling by providing a rationale for how and why body weight and/or appetite is influenced. Dietitians can expand their knowledge of weight physiology and neurohormonal factors that affect appetite and eating behaviours by staying up to date with emerging evidence while providing patients/clients with education and support with goals to reduce weight bias and stigma. 

See Additional Content: Weight Stigma Background.

Resources for Professionals
Clinical practice guidelines, web links and other professional tools and resources can be found under the Weight/Obesity Related Tools and Resources tab. Use the Audience, Country and Language sort buttons to narrow your search.  

  1. Puhl RM, Heuer CA. The stigma of obesity: a review and update. Obesity (Silver Spring). 2009 May;17(5):941-64. Available from:
  2. Moyer VA, on behalf of the United States Preventive Services Task Force Screening for and management of obesity in Adults: U.S. preventive services task force recommendation statement. Ann Intern Med. 2012;157:1-32. Abstract available from:
  3. Public Health Agency of Canada. Obesity in Canada – Health and economic implications. 2011. Available from: 
  4. Edholm OG, Fletcher JG, Widdowson EM, Mccance RA. The energy expenditure and food intake of individual men. Br J Nutr. 1955;9(3):286-300. Abstract available from:
  5. Edholm OG. Energy balance in man studies carried out by the Division of Human Physiology, National Institute for Medical Research. J Hum Nutr. 1977 Dec;31(6):413-31. Abstract available from:
  6. Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation. 2012 Jul 3;126(1):126-32. Available from:
  7. Lustig RH. The efferent arm of the energy balance regulatory pathway: neuroendocrinology and pathology. In: Donohoue PA, editor. Energy metabolism and obesity. Totowa, NJ: Humana Press; 2008. p. 69-85. Available from:
  8. Kitahara CM, Flint AJ, Berrington de Gonzalez A, Bernstein L, Brotzman M, MacInnis RJ, et al. Association between class III obesity (BMI of 40-59 kg/m2) and mortality: A pooled analysis of 20 prospective studies. PLoS Med. 2014;11(7):e1001673. Abstract available from:
  9. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, Wormser D, Gao P, Kaptoge S, Berrington de Gonzalez A, et al. Body-mass index and all-cause mortality: Individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776-786. Abstract available from:
  10. Anis AH, Zhang W, Bansback N, Guh DP, Amarsi Z, Birmingham CL. Obesity and overweight in Canada: An updated cost-of-illness study. Obes Rev. 2010;11(1):31-40. Abstract available from:
  11. Gupta S, Richard L, Forsythe A. The humanistic and economic burden associated with increasing body mass index in the EU5. Diabetes Metab Syndr Obes Targets Ther. 2015;8:327-338. Abstract available from:
  12. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis. BMC Public Health. 2009;9:88. Abstract available from:
  13. Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89(3):309-319. Available from:
  14. Aune D, Greenwood DC, Chan DSM, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: A systematic review and non-linear dose-response meta-analysis of prospective studies. Ann Oncol. 2012;23(4):843-852. Abstract available from:
  15. Aune D, Navarro Rosenblatt DA, Chan DS, Abar L, Vingeliene S, Vieira AR, et al. Anthropometric factors and ovarian cancer risk: A systematic review and nonlinear dose-response meta-analysis of prospective studies. Int J Cancer. 2015;136(8):1888-1898. Abstract available from:
  16. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric factors and endometrial cancer risk: A systematic review and dose-response meta-analysis of prospective studies. Ann Oncol. 2015;26(8):1635-1648. Abstract available from:
  17. Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15(6):556-565. Abstract available from:
  18. Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, Qizilbash N, Collins R, Peto R. Body-mass index and cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373(9669):1083-1096. Abstract available from:
  19. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring). 2014 Jul;22 Suppl 2:S41-410. doi: 10.1002/oby.20660. PMID: 24227637. Citation available from:
  20. Twells LK, Janssen I, Kuk JL. Canadian Adult Obesity Clinical Practice Guidelines: Epidemiology of Adult Obesity. 2020. Available from: 
  21. Kramer C, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159(11):758-769. Abstract available from:
  22. Phillips CM. Metabolically healthy obesity across the life course: Epidemiology, determinants, and implications. Ann N Y Acad Sci. 2017;1391(1):85-100. Abstract available from:
  23. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med. 2008;168(15):1617-1624. Abstract available from:
  24. Wharton S, Lau DCW, Vallis M, Sharma AM, Biertho L, Campbell-Scherer D, et al. Obesity in Adults: A Clinical Practice Guideline. CMAJ. 2020;192(31):E875-E891. Available from:
  25. Rueda-Clausen CF, Poddar M, Lear SA, Poirier P, Sharma AM. Canadian Adult Obesity Clinical Practice Guidelines: Assessment of People Living with Obesity. 20202. Available from:
  27. Sharma AM, Campbell-Scherer DL. Redefining obesity: beyond the numbers. Obesity (Silver Spring). 2017;25(4):660-1. Abstract available from:
  28. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. The American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity: Executive Summary. Endocr Pract. 2016;22(7):842-84. Available from:
  29. Frühbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J, et al. The ABCD of Obesity: an EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts. 2019 Mar 7;12(2):131-6. Abstract available from:
  30. AMA Declares Obesity a Disease. 2013. Available from:
  31. Canadian Medical Association. Obesity as a chronic medical disease. 2015. Available from: 
  32. Yumuk V, Tsigos C, Fried M, Schindler K, Busetto L, Micic D, et al. European guidelines for obesity management in adults. Obes Facts. 2015 Dec 5;8(6):402-24. Abstract available from:
  33. Durrer Schutz D, Busetto L, Dicker D, Farpour-Lambert N, Pryke R, Toplak H, et al. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obes Facts. 2019 Jan 23;12(1):40-66. Abstract available from:
  34. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017 Jul;18(7):715-723. doi: 10.1111/obr.12551. Epub 2017 May 10. PMID: 28489290. Abstract available from:
  35. ASMBS. Disease of Obesity. Patients. [cited 2019 Sep 8]. Available from:
  36. Obesity Canada. Yukon Medical Association Becomes Second PTMA to Recognize Obesity as a Chronic Disease. 2018 Nov. Available from:
  37. WHO European Regional Obesity Report 2022. Copenhagen: WHO Regional Office for Europe; 2022. Licence:CC BY-NC-SA 3.0 IGO. Available from:
  38. The European Association for the Study of Obesity. Obesity now recognized as a chronic disease in Italy. 2019 Nov 18. Available from:,improve%20obesity%20prevention%20and%20management 
  39. The European Association for the Study of Obesity. German Parliament Recognizes Obesity as a Chronic Disease. 2020 July. Available from: 
  40. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet. 2005;94:1-12. doi: 10.1159/000088200. PMID: 16145245. Available from:
  41. Serviço Nacional de Saúde. Obesity as a disease. 2004. Link not available. 
  42. Sones M. Israel Medical Association declares obesity a disease. Israel National News. 2018. Available from:
  43. Royal College of Physicians. RCP calls for obesity to be recognised as a disease. 2019. Available from:
  44. Kyle TK, Dhurandhar EJ, Allison DB. Regarding obesity as a disease: evolving policies and their implications. Endocrinol Metab Clin North Am. 2016;45(3):511-20. Abstract available from:
  45. Meadows A, Daníelsdóttir S. What’s in a word? on weight stigma and terminology. Front Psychol. 2016 Oct 5;7:1527. Available from:
  46. McPhail D, Orsini M. Fat acceptance as social justice. CMAJ. 2021;193(35):E1398-E1399; doi: 10.1503/cmaj.210772. Citation available from:
  47. Bessey M, Lordly D. Weight Inclusive Practice: Shifting the Focus from Weight to Social Justice. Can J Diet Pract Res. 2020 Sep 1;81(3):127-131. doi: 10.3148/cjdpr-2019-034. Epub 2019 Nov 18. Abstract available from:
  48. Garvey WT, Mechanick JI. Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity. Obesity 2020:28:484-492. Abstract available from:
  49. Luig T, Elwyn G, Anderson R, Campbell-Scherer DL. Facing obesity: Adapting the collaborative deliberation model to deal with a complex long-term problem. Patient Educ Couns. 2019;102(2):291-300. Abstract available from:
  50. Luig T, Anderson R, Sharma AM, Campbell-Scherer DL. Personalizing obesity assessment and care planning in primary care: patient experience and outcomes in everyday life and health. Clin Obes. 2018 Dec;8(6):411-23. Abstract available from:
  51. Ramos Salas X, Forhan M, Caulfield T, Sharma AM, Raine K. A critical analysis of obesity prevention policies and strategies. Can J Public Health. 2018 Jan 22;108(5-6):e598-608. Abstract available from:
  52. Khasteganan N, Lycett D, Furze G, Turner AP. Health, not weight loss, focused programmes versus conventional weight loss programmes for cardiovascular risk factors: a systematic review and meta-analysis. Syst Rev. 2019 Aug 10;8(1):200. Abstract available from:
  53. Ma X, Lee P, Chisholm DJ, James DE. Control of adipocyte differentiation in different fat depots; Implications for pathophysiology or therapy. Front Endocrinol (Lausanne). 2015;6:1-8. Abstract available from:
  54. Kahn CR, Wang G, Lee KY. Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest. 2019 Oct 1;129(10):3990-4000. doi: 10.1172/JCI129187. PMID: 31573548; PMCID: PMC6763230. Abstract available from:
  55. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021 Mar 1;320(3):C375-C391. doi: 10.1152/ajpcell.00379.2020. Epub 2020 Dec 23. PMID: 33356944; PMCID: PMC8294624. Abstract available from:
  56. Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong AP, Chan RS, et al. Fatty pancreas, insulin resistance, and β-cell function: a population study using fat-water magnetic resonance imaging. Am J Gastroenterol. 2014 Apr;109(4):589-97. doi: 10.1038/ajg.2014.1. Epub 2014 Feb 4. PMID: 24492753. Abstract available from:
  57. Münzberg H, Morrison CD. Structure, production and signaling of leptin. Metab Clin Exp. 2015;64(1):13-23. Abstract available from:
  58. Friedman JM. The function of leptin in nutrition, weight, and physiology. Nutr Rev. 2002;60(10 pt 2):S1-S14. Abstract available from:
  59. Myers MG, Cowley MA, Münzberg H. Mechanisms of leptin action and leptin resistance. Annu Rev Physiol. 2008;70:537-556. Abstract available from:
  60. Farooqi IS, O’Rahilly S. 20 years of leptin: human disorders of leptin action. J Endocrinol. 2014;223(1):T63-T70. Abstract available from:
  61. Flier JS, Maratos-Flier E. Leptin’s physiologic role: does the emperor of energy balance have no clothes? Cell Metab. 2017;26(1):24-26. Abstract available from:
  62. Friedman JM. Leptin and the endocrine control of energy balance. Nat Metab. 2019 Aug;1(8):754-764. Abstract available from:
  63. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. Nature. 2015 Feb 12;518(7538):197-206. Abstract available from:
  64. Hu FB. Genetic predictors of obesity. In: Hu F, editor. Obesity Epidemiology. Oxford University Press; 2008. p. 437-60. Link not available. 
  65. Loos RJF, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet. 2008 Jun;40(6):768-75. Abstract available from:
  66. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Mägi R, et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature. 2015 Feb 12;518(7538):187-96. Abstract available from:
  67. Farooqi S, O’Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006 Dec;27(7):710-8. Available from:
  68. Ayers KL, Glicksberg BS, Garfield AS, Longerich S, White JA, Yang P, et al. Melanocortin 4 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2601-12. Abstract available from:
  69. Lopomo A, Burgio E, Migliore L. Epigenetics of Obesity. Prog Mol Biol Transl Sci. 2016;140:151-84. Abstract available from:
  70. Thaler JP, Yi C-X, Schur EA, Guyenet SJ, Hwang BH, Dietrich MO, et al. Obesity is associated with hypothalamic injury in rodents and humans. J Clin Invest. 2012 Jan;122(1):153-62. Abstract available from:
  71. Bray MS, Loos RJF, McCaffery JM, Ling C, Franks PW, Weinstock GM, et al. NIH working group report-using genomic information to guide weight management: From universal to precision treatment. Obesity (Silver Spring). 2016 Jan;24(1):14-22. Abstract available from:
  72. Loos RJF. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab. 2012 Apr;26(2):211-26. Abstract available from:
  73. Kilpeläinen TO, Qi L, Brage S, Sharp SJ, Sonestedt E, Demerath E, et al. Physical activity attenuates the influence of FTO variants on obesity risk: a meta-analysis of 218,166 adults and 19,268 children. PLoS Med. 2011 Nov 1;8(11):e1001116. Abstract available from:
  74. Coll AP, Farooqi IS, Challis BG, Yeo GS, O'Rahilly S. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab. 2004 Jun;89(6):2557-62. doi: 10.1210/jc.2004-0428. PMID: 15181023. Abstract available from: 
  75. Mendiratta MS, Yang Y, Balazs AE, Willis AS, Eng CM, Karaviti LP, Potocki L. Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. Int J Pediatr Endocrinol. 2011;2011(1):5. doi: 10.1186/1687-9856-2011-5. Epub 2011 Jul 6. PMID: 21860632; PMCID: PMC3159139. Abstract available from:
  76. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, Lank E, Bottomley B, Lopez-Fernandez J, Ferraz-Amaro I, Dattani MT, Ercan O, Myhre AG, Retterstol L, Stanhope R, Edge JA, McKenzie S, Lessan N, Ghodsi M, De Rosa V, Perna F, Fontana S, Barroso I, Undlien DE, O'Rahilly S. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007 Jan 18;356(3):237-47. doi: 10.1056/NEJMoa063988. PMID: 17229951; PMCID: PMC2670197. Abstract available from:
  77. Forsythe E, Beales PL. Bardet-Biedl syndrome. Eur J Hum Genet. 2013 Jan;21(1):8-13. doi: 10.1038/ejhg.2012.115. Epub 2012 Jun 20. PMID: 22713813; PMCID: PMC3522196. Abstract available from:
  78. Pomeroy J, Krentz AD, Richardson JG, Berg RL, VanWormer JJ, Haws RM. Bardet-Biedl syndrome: Weight patterns and genetics in a rare obesity syndrome. Pediatr Obes. 2021 Feb;16(2):e12703. doi: 10.1111/ijpo.12703. Epub 2020 Jul 22. PMID: 32700463; PMCID: PMC7816264. Abstract available from:
  79. Paisey RB, Steeds R, Barrett T, D, , Alström Syndrome. GeneReviews®. 2019 June 13. Available from:
  80. Müller MJ, Enderle J, Bosy-Westphal A. Changes in Energy Expenditure with Weight Gain and Weight Loss in Humans. Curr Obes Rep. 2016 Dec;5(4):413-423. doi: 10.1007/s13679-016-0237-4. PMID: 27739007; PMCID: PMC5097076. Abstract available from:
  81. Dhurandhar EJ, Kaiser KA, Dawson JA, Alcorn AS, Keating KD, Allison DB. Predicting adult weight change in the real world: a systematic review and meta-analysis accounting for compensatory changes in energy intake or expenditure. Int J Obes (Lond). 2015 Aug;39(8):1181-7. Abstract available from:
  82. Kennedy GC. The hypothalamus and obesity. Proc R Soc Med. 1966 Dec;59(12):1276-7. Abstract available from:
  83. Keys A. Experimental human starvation; general and metabolic results of a loss of one fourth the body weight in six months. Fed Proc. 1946;5(1 Pt 2):55. Abstract available from:
  84. Tremblay A, Doucet E. Obesity: a disease or a biological adaptation? Obes Rev. 2000 May;1(1):27-35. Abstract available from:
  85. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017 Apr 13;376(15):1492. Abstract available from:
  86. Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond, B, Biol Sci. 1953 Jan 15;140(901):578-96. Abstract available from:
  87. O’Rahilly S, Farooqi IS. Human obesity: a heritable neurobehavioral disorder that is highly sensitive to environmental conditions. Diabetes. 2008 Nov;57(11):2905-10. Abstract available from:
  88. Young EH, Wareham NJ, Farooqi S, Hinney A, Hebebrand J, Scherag A, et al. The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals. Int J Obes (Lond). 2007 Sep;31(9):1437-41. Abstract available from:
  89. Rovite V, Petrovska R, Vaivade I, Kalnina I, Fridmanis D, Zaharenko L, et al. The role of common and rare MC4R variants and FTO polymorphisms in extreme form of obesity. Mol Biol Rep. 2014 Mar;41(3):1491-500. Abstract available from:
  90. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. Abstract available from:
  91. MacLean PS, Higgins JA, Giles ED, Sherk VD, Jackman MR. The role for adipose tissue in weight regain after weight loss. Obes Rev. 2015 Feb;16 Suppl 1:45–54. Abstract available from:
  92. Seeley RJ, Berridge KC. The hunger games. Cell. 2015 Feb 26;160(5):805-6. Abstract available from:
  93. Leibel RL, Seeley RJ, Darsow T, Berg EG, Smith SR, Ratner R. Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium. Diabetes. 2015 Jul;64(7):2299-309. doi: 10.2337/db15-0004. PMID: 26106187.
    Abstract available from:
  94. Thomas DM, Martin CK, Lettieri S, Bredlau C, Kaiser K, Church T, Bouchard C, Heymsfield SB. Can a weight loss of one pound a week be achieved with a 3500-kcal deficit? Commentary on a commonly accepted rule. Int J Obes (Lond). 2013 Dec;37(12):1611-3. doi: 10.1038/ijo.2013.51. Epub 2013 Apr 8. PMID: 23628852; PMCID: PMC4024447. Abstract available from:
  95. Hall KD, Chow CC. Why is the 3500 kcal per pound weight loss rule wrong? Int J Obes. 2013;37(12):1614. Available from:
  96. Schwartz A, Doucet E. Relative changes in resting energy expenditure during weight loss: a systematic review. Obes Rev. 2010 Jul;11(7):531-47. Abstract available from:
  97. Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? quantification of the feedback control of human energy intake. Obesity (Silver Spring). 2016;24(11):2289-95. Abstract available from:
  98. Schwartz MW, Seeley RJ, Zeltser LM, Drewnowski A, Ravussin E, Redman LM, et al. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev. 2017 Aug 1;38(4):267-96. Abstract available from:
  99. Perry B, Wang Y. Appetite regulation and weight control: the role of gut hormones. Nutr Diabetes. 2012 Jan 16;2:e26. Abstract available from:
  100. MacLean PS, Higgins JA, Jackman MR, Johnson GC, Fleming-Elder BK, Wyatt HR, et al. Peripheral metabolic responses to prolonged weight reduction that promote rapid, efficient regain in obesity-prone rats. Am J Physiol Regul Integr Comp Physiol. 2006 Jun;290(6):R1577-88. Abstract available from:
  101. Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci. 2013 Feb;124(4):231-41. Abstract available from:
  102. Zhao X, Han Q, Gang X, Lv Y, Liu Y, Sun C, Wang G. The Role of Gut Hormones in Diet-Induced Weight Change: A Systematic Review. Horm Metab Res. 2017 Nov;49(11):816-825. Abstract available from:
  103. Bray GA. Effect of caloric restriction on energy expenditure in obese patients. Lancet. 1969 Aug 23;2(7617):397-8. Available from:
  104. Scott R, Tan T, Bloom S. Gut hormones and obesity: physiology and therapies. Vitam Horm. 2013;91:143-94. Abstract available from:
  105. Ochner CN, Kwok Y, Conceição E, Pantazatos SP, Puma LM, Carnell S, et al. Selective reduction in neural responses to high calorie foods following gastric bypass surgery. Ann Surg. 2011 Mar;253(3):502-7. Abstract available from:
  106. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002 May 23;346(21):1623-30. Abstract available from:
  107. Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010 Apr;110(4):571-84. Abstract available from:
  108. Anderson B, Switzer NJ, Almamar A, Shi X, Birch DW, Karmali S. The impact of laparoscopic sleeve gastrectomy on plasma ghrelin levels: a systematic review. Obes Surg. 2013;23(9):1476-1480. Abstract available from:
  109. Stefanidis A, Oldfield BJ. Neuroendocrine mechanisms underlying bariatric surgery: Insights from human studies and animal models. J Neuroendocrinol. 2017 Oct;29(10). Abstract available from:
  110. Morínigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R, Gomis R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly obese subjects. Ann Surg. 2008 Feb;247(2):270-5. Abstract available from:
  111. le Roux CW, Aylwin SJB, Batterham RL, Borg CM, Coyle F, Prasad V, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006 Jan;243(1):108-14. Abstract available from:
  112. Koliaki C, Liatis S, Dalamaga M, Kokkinos A. The Implication of Gut Hormones in the Regulation of Energy Homeostasis and Their Role in the Pathophysiology of Obesity. Curr Obes Rep. 2020 Sep;9(3):255-271. Abstract available from:
  113. Rebello CJ, Greenway FL. Obesity medications in development. Expert Opin Investig Drugs. 2020 Jan;29(1):63-71. doi: 10.1080/13543784.2020.1705277. Epub 2019 Dec 19. PMID: 31847611;PMCID: PMC6990416. Abstract available from:
  114. Markham A. Setmelanotide: First Approval. Drugs. 2021 Feb;81(3):397-403. doi: 10.1007/s40265-021-01470-9. PMID: 33638809. Abstract available from:
  115. Brown J, Clarke C, Johnson Stoklossa C, Sievenpiper J. Canadian Adult Obesity Clinical Practice Guidelines: Medical Nutrition Therapy in Obesity Management. 2020 Dec 4. Available from:

Target Group: All Adults, All children(0-12 yr.), Youth(13-17 yr.)
Knowledge Pathways: Weight/Obesity, Weight/Obesity - Assessment, Weight/Obesity - Dietary Approaches, Weight/Obesity - Dietary Supplements, Weight/Obesity - Pediatric/Paediatric, Weight/Obesity - Pediatric/Paediatric: Prevention
 Last Updated: 2022-06-28

Current Contributors


Jennifer Brown - Author

Lindsey Mazur - Author

Helen Croker - Reviewer

Jennifer Brady - Reviewer

Judy Bauer - Reviewer

Maria Ricupero - Reviewer

Natalie Stapleton - Reviewer

Paula Brauer - Reviewer